Another small study focused on 45 patients harboring core-binding factor (CBF) AML that received an allogeneic or autologous HSCT and evaluated BAALC/ABL1 expression levels in bone marrow at diagnosis, as well as in CR after the first induction cycle, pre-HSCT, and at day 60 post-HSCT. This evidence concerns the gene BAALC and acute myeloid leukemia.